A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Active, not recruiting · NCT06550895 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-09-25 | NCT06550895 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Research & Development, LLC | 188 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Austin Hospital | Heidelberg | Australia | 11 |
| Barbara Ann Karmanos Cancer Institute | Detroit | United States | 44 |
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |
| Norton Cancer Institute | Louisville | United States | 37 |
| Peter MacCallum Cancer Centre | Melbourne | Australia | 32 |
| Royal Prince Alfred Hospital | Camperdown | Australia | 19 |
| The Alfred Hospital | Melbourne | Australia | 26 |
| University of Iowa Hospital and Clinics | Iowa City | United States | 30 |
| University of Pennsylvania | Philadelphia | United States | 507 |